Form 4: CRISPR Therapeutics Executive James R. Kasinger Reports Stock Transactions
SEC Form 4 Filing
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Summary
- On March 10, 2024, James R. Kasinger vested 5,500 restricted stock units (RSUs) which converted into common shares.
- On March 11, 2024, Kasinger sold 2,801 common shares at a price of $78.26 to cover tax withholding obligations related to the vesting of RSUs.
- Also on March 11, 2024, Kasinger vested 2,250 restricted stock units (RSUs) which converted into common shares.
- On March 12, 2024, Kasinger sold 1,146 common shares at a price of $74.44 to cover tax withholding obligations related to the vesting of RSUs.
- Following these transactions, Kasinger directly owns 61,174 common shares.
Sentiment
Score: 5
Explanation: The document primarily reports routine stock transactions related to vesting and tax obligations, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Comparison to Industry Standards
- Tracking insider transactions is a common practice in financial analysis, with services like Bloomberg and FactSet providing data and analytics on insider trading activity.
- Comparing Kasinger's transactions to those of other executives at CRISPR Therapeutics and similar gene editing companies (e.g., Intellia Therapeutics, Editas Medicine) could provide insights into management's overall sentiment and expectations for the company's future performance.
- The sale of shares to cover tax obligations is a routine occurrence, especially after the vesting of restricted stock units.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased number of shares in the market, but the impact is likely to be minimal given the relatively small volume of shares sold.
Key Dates
| Date | Description |
|---|---|
| 03/10/2023 | Date of grant for 22,000 Common Shares, with one quarter of the shares vesting on March 10, 2024. |
| 03/11/2021 | Date of grant for 9,000 Common Shares, with one quarter of the shares vesting on March 11, 2022. |
| 03/10/2024 | Vesting of 5,500 restricted stock units. |
| 03/11/2024 | Sale of 2,801 common shares at $78.26 and vesting of 2,250 restricted stock units. |
| 03/12/2024 | Sale of 1,146 common shares at $74.44. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.